Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextrothyroxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 11/20 | 0.76 |
| ▸ | THRA known ✓ | P10827 | 7/20 | 0.76 |
| ▸ | MEN1 | O00255 | 7/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.76 |
| ▸ | PPARG | P37231 | 5/20 | 0.76 |
| ▸ | USP2 | O75604 | 4/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.76 |
| ▸ | TTR | P02766 | 2/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | RXRA | P19793 | 2/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrothyroxine SCHEMBL5498887 | 1.00 | THRB (0.76) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL1995243 | 1.00 | THRB (0.76) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL34102 | 1.00 | THRB (0.76) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL7112166 | 0.99 | USP2 (0.76) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL2327406 | 0.99 | USP2 (0.76) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL838270 | 0.99 | USP2 (0.76) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL1560691 | 0.95 | THRB (0.86) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL4965467 | 0.95 | THRB (0.86) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL15569465 | 0.92 | THRB (0.91) | THRBMEN1KMT2ATHRALMNA | |
| Dextrothyroxine SCHEMBL4437395 | 0.88 | THRB (0.61) | THRBMEN1KMT2ATHRALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1010 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339259-A1 | ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF | SHEN HAIFA (US) | 2022-10-27 | — | — | US | claimed |
| CN-114466658-A | Orally delivered therapeutic compositions and uses thereof | 沈海发 | 2022-05-10 | — | — | CN | claimed |
| WO-2021046497-A2 | ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF | SHEN HAIFA (US) | 2021-03-11 | — | — | WO | claimed |
| US-9895357-B2 | Compositions, methods and kits for reducing lipid levels | NUSIRT SCIENCES, INC. (US) | 2018-02-20 | — | — | US | claimed |
| US-20170340615-A1 | COMPOSITIONS, METHODS AND KITS FOR REDUCING LIPID LEVELS | NUSIRT SCIENCES, INC. | 2017-11-30 | — | — | US | claimed |
| US-9585876-B2 | Leucine and nicotinic acid reduces lipid levels | NUSIRT SCIENCES, INC. (US) | 2017-03-07 | — | — | US | claimed |
| CN-106074550-A | A kind of medicine treating hypothyroidism | 朱德发 | 2016-11-09 | — | — | CN | claimed |
| CN-104825397-A | Controlled release delivery device containing organosol coating | ISA ODIDI | 2015-08-12 | — | — | CN | claimed |
| US-8591947-B2 | Dual controlled release dosage form | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2013-11-26 | — | — | US | claimed |
| US-20130108693-A1 | Dual Controlled Release Dosage Form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2013-05-02 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20040101829-A1 | Protein that interacts with lipids and methods for treating hyperlipidemia | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2004-05-27 | — | — | US | claimed |
| WO-2004003141-A2 | A PROTEIN THAT INTERACTS WITH LIPIDS AND METHODS FOR TREATING HYPERLIPIDEMIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2004-01-08 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6190696-B1 | MIXING LIOTHYRONINE SODIUM, IODINE SALT MIXED WITH CARRIER, DISINTEGRANT, LUBRICANT, BINDER AND FILLER | GROENEWOUD PIETER J (US) | 2001-02-20 | — | — | US | claimed |
| WO-1999063969-A1 | STABILIZED THYROXINE MEDICATIONS | GROENEWOUD PIETER J (US) | 1999-12-16 | — | — | WO | claimed |
| US-4690824-A | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range | REDI-ROWELL, INC. (US) | 1987-09-01 | — | — | US | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339259-A1 | ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF | FABP2, SLC27A1, SLC27A2 | THRB 4646/4885THRA 4543/4885MEN1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.